Aspira Women’s Health (NASDAQ:AWH) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a report published on Sunday. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners reduced their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, August 14th.

Aspira Women’s Health Stock Down 3.5 %

Shares of NASDAQ:AWH opened at $0.83 on Friday. Aspira Women’s Health has a 52 week low of $0.67 and a 52 week high of $5.65. The company has a 50 day moving average price of $0.84 and a two-hundred day moving average price of $1.22.

Institutional Investors Weigh In On Aspira Women’s Health

An institutional investor recently bought a new position in Aspira Women’s Health stock. Pine Valley Investments Ltd Liability Co bought a new position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 31,200 shares of the company’s stock, valued at approximately $25,000. Pine Valley Investments Ltd Liability Co owned 0.19% of Aspira Women’s Health at the end of the most recent reporting period. 12.19% of the stock is currently owned by institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.